Teligene Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 61

Employees

  • Latest Deal Type
  • IPO
  • (Cancelled)

  • Investors
  • 13

Teligene General Information

Description

Developer and researcher of small-molecule drugs intended to improve cancer patient outcomes. The company is dedicated to develop innovative therapeutic approaches in oncology and small-molecule anti-tumor drugs, aiming to provide high-quality research and pharmaceutical products for healthcare practitioners to improve the lives of cancer patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Unit 416, Building A4, Bio-Nano Park
  • No. 218 Xinghu Street
  • Suzhou, Jiangsu 215123
  • China
+86 0512
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • Unit 416, Building A4, Bio-Nano Park
  • No. 218 Xinghu Street
  • Suzhou, Jiangsu 215123
  • China
+86 0512

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Teligene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. IPO 20-Jun-2023 Cancelled Clinical Trials - General
8. Later Stage VC 10-Feb-2021 Completed Clinical Trials - General
7. Secondary Transaction - Private 29-Jan-2021 Completed Clinical Trials - General
6. Secondary Transaction - Private 17-Sep-2020 Completed Clinical Trials - General
5. Later Stage VC (Series C) 17-Aug-2018 Completed Clinical Trials - General
4. Later Stage VC 06-Jul-2017 Completed Clinical Trials - General
3. Later Stage VC 01-Jun-2017 Completed Clinical Trials - General
2. Secondary Transaction - Private 23-Aug-2016 Completed Clinical Trials - General
1. Early Stage VC 01-Apr-2012 Completed Clinical Trials - General
To view Teligene’s complete valuation and funding history, request access »

Teligene Patents

Teligene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4831160-A1 Trisubstituted quinazoline derivative, acid addition salt thereof, and pharmaceutical composition and use thereof Pending 05-Feb-2024
WO-2025167927-A1 Trisubstituted quinazoline derivative, acid addition salt thereof, and pharmaceutical composition and use thereof Pending 05-Feb-2024
EP-3844166-A1 Substituted macrocycles useful as kinase inhibitors Active 14-May-2019
EP-3844166-A4 Substituted macrocycles useful as kinase inhibitors Active 14-May-2019
EP-3844166-B1 Substituted macrocycles useful as kinase inhibitors Active 14-May-2019 A61K45/06
To view Teligene’s complete patent history, request access »

Teligene Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Teligene Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alan Asset Management Asset Manager Minority
China Reform Holdings Corporation Corporation Minority
CICC Jia Cheng Investment Management Company Venture Capital Minority
Global X VC-Backed Company Minority
Kangcheng Capital Growth/Expansion Minority
You’re viewing 5 of 13 investors. Get the full list »

Teligene FAQs

  • When was Teligene founded?

    Teligene was founded in 2011.

  • Where is Teligene headquartered?

    Teligene is headquartered in Suzhou, China.

  • What is the size of Teligene?

    Teligene has 61 total employees.

  • What industry is Teligene in?

    Teligene’s primary industry is Pharmaceuticals.

  • Is Teligene a private or public company?

    Teligene is a Private company.

  • What is Teligene’s current revenue?

    The current revenue for Teligene is .

  • How much funding has Teligene raised over time?

    Teligene has raised $123M.

  • Who are Teligene’s investors?

    Alan Asset Management, China Reform Holdings Corporation, CICC Jia Cheng Investment Management Company, Global X, and Kangcheng Capital are 5 of 13 investors who have invested in Teligene.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process